TrialBlood2021

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.

Philippe Armand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.